Please ensure Javascript is enabled for purposes of website accessibility

Why Pacific Biosciences of California Went Up, Then Down, Then Sideways

By Brian Orelli, PhD - Oct 27, 2015 at 3:05PM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

It can be hard to value a company at its inflection point.

What: Pacific Biosciences of California (PACB -10.74%) jumped 9.6% on Friday after releasing earnings on Thursday night, and then proceeded to give back the entire gain and then some on Monday. Things have calmed down today.

PACB Price Chart

So what: Welcome to owning companies that are hard to value.

Pacific Biosciences is clearly worth more having launched its new DNA sequencing Sequel System than it was pre-launch. At a cheaper price than the older RS II system, Pacific Biosciences should be able to take some of Illumina's (ILMN -3.02%) market share. The RS II was really limited to applications that couldn't be performed on Illumina's machines because it was so much more expensive.

The cheaper cost of sequencing should help convert some users away from the Illumina's machines. The longer sequencing reads that Pacific Biosciences machines produce are more useful than Ilumina's short reads. But it's hard to tell how much and how quickly Pacific Biosciences can convert that business.

The other unknown comes from Pacific Biosciences' deal with Roche. Again, having the Sequel System that Roche will use as a basis for developing diagnostic tests makes Pacific Biosciences more valuable than without the system, but it's hard to estimate how many additional sales could come from the deal.

Part of the decline on Monday might come from investors worrying about the potential for a secondary offering that would dilute current shareholders. Pacific Biosciences ended the quarter with about $59 million, having burned through just under $14 million in the third quarter.

The company expects a $20 million payment from Roche in the fourth quarter, so it's certainly not under pressure to raise capital before the end of the year. But there's an adage that non-profitable companies should raise when they can, not when they have to. With shares up more than 75% over the last month, it would be hard to blame management if it raised here.

Now what: Investors would be best off ignoring the daily movements from Pacific Biosciences. We'll get an early idea of demand for the Sequel Systems when the company reports fourth quarter earnings, but we won't really know how much the systems are being used until they're in place and we see sales of consumables used by the machines in future quarters. The Roche story is even longer-term with a launch for clinical research scheduled for the second half of next year.

Brian Orelli has no position in any stocks mentioned. The Motley Fool recommends Illumina and Pacific Biosciences of California. Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

Illumina, Inc. Stock Quote
Illumina, Inc.
ILMN
$202.75 (-3.02%) $-6.31
Pacific Biosciences of California, Inc. Stock Quote
Pacific Biosciences of California, Inc.
PACB
$6.40 (-10.74%) $0.77

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning analyst team.

Stock Advisor Returns
397%
 
S&P 500 Returns
128%

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 08/19/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.